ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)
Previous Close
$16.21
52W Range
$14.15 - $32.59
50D Avg
$15.60
200D Avg
$17.39
Market Cap
$2.71B
Avg Vol (3M)
$1.37M
Beta
0.38
Div Yield
-
ACAD Company Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACAD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AKRO | Akero Therapeutics, Inc. |
| PTCT | PTC Therapeutics, Inc. |
| BPMC | Blueprint Medicines Corporation |
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| SRPT | Sarepta Therapeutics, Inc. |
| FBIO | Fortress Biotech, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| CABA | Cabaletta Bio, Inc. |
| VKTX | Viking Therapeutics, Inc. |
| ATHA | Athira Pharma, Inc. |
| KRYS | Krystal Biotech, Inc. |
| HEPA | Hepion Pharmaceuticals, Inc. |
| MDGL | Madrigal Pharmaceuticals, Inc. |